Quantcast
Last updated on April 16, 2014 at 1:21 EDT

Latest Renal cell carcinoma Stories

2012-06-04 19:20:21

Agent benefits melanoma and lung cancer as well An antibody that helps a person's own immune system battle cancer cells shows increasing promise in reducing tumors in patients with advanced kidney cancer, according to researchers at Beth Israel Deaconess Medical Center. The results of an expanded Phase 1 trial presented at the American Society of Clinical Oncology's annual conference in Chicago, showed that some patients treated with a fully human monoclonal antibody developed by...

2012-06-02 23:01:47

• Clinical Activity of Anti-PD-1 Published in New England Journal of Medicine (NEJM) and Presented at 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) • Phase 1 Data on Second Investigational Immunotherapy (Anti-PD-L1) Also Published in NEJM and Presented at ASCO Milwaukee, WI (PRWEB) June 02, 2012 SITC leaders publish landmark studies of new cancer immunotherapeutics Clinical activity of two cancer immunotherapeutic agents, anti-PD-1 and anti-PD-L1 were...

2012-05-24 22:20:28

TUEBINGEN, Germany, May 25, 2012 /PRNewswire/ -- immatics chosen as a leading company in the life sciences category by the world's largest entrepreneurial network immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that it has been named a 2012 TiE50 winner. These prestigious awards recognize entrepreneurship, innovation and...

2012-05-23 17:15:13

Magnetic resonance imaging (MRI) provides an indication of a breast tumor's response to pre-surgical chemotherapy significantly earlier than possible through clinical examination, according to a new study published online in the journal Radiology. Women with breast cancer often undergo chemotherapy prior to surgery. Research has shown that women who receive this treatment, known as neoadjuvant chemotherapy, are more likely to achieve breast conservation than those receiving chemotherapy...

2012-05-23 05:37:19

(Ivanhoe Newswire) — A new study shows that magnetic resonance imaging (MRI), when compared with clinical examination, can actually give an earlier indication of a breast tumor´s response to pre-surgical chemotherapy. Research shows that women who receive chemotherapy before surgery, known as neoadjuvant chemotherapy, are more likely to achieve breast conservation compared with those receiving chemotherapy after surgery. Traditionally, clinicians monitor the patient´s...

2012-05-17 23:03:57

Mount Sinai School of Medicine researchers will present several landmark studies, including data on treatment trends in late-stage cancer, HPV-positive head and neck cancer, a promising multiple myeloma vaccine, and predictive models of soft tissue sarcomas, prostate and bladder cancer, at the 2012 American Society of Clinical Oncology (ASCO) meeting June 1-5, 2012 in Chicago. New York, NY (PRWEB) May 17, 2012 Mount Sinai School of Medicine researchers will present several landmark studies,...

2012-05-17 14:18:12

Landmark research presented at annual cancer meeting Mount Sinai School of Medicine researchers will present several landmark studies, including data on treatment trends in late-stage cancer, a promising multiple myeloma vaccine, and predictive models of soft tissue sarcomas, prostate and bladder cancer, at the 2012 American Society of Clinical Oncology (ASCO) meeting June 1-5, 2012 in Chicago. Highlights of Mount Sinai research at ASCO: Age, Race, Lower Income, and Lack of...

2012-05-03 15:11:39

Presentations at the 4th IMPAKT Breast Cancer Conference A new analysis may help doctors identify breast cancer patients who will benefit from treatment with the immune suppressant drug everolimus, say French researchers at the 4th IMPAKT Breast Cancer Conference in Brussels, Belgium. Everolimus is currently used as an immunosuppressant to prevent patients rejecting transplanted organs and in the treatment of renal cell cancer. Research is also being conducted into the drug's use in...

2012-04-24 02:29:49

DURHAM, N.C., April 24, 2012 /PRNewswire/ -- Argos Therapeutics Inc. today announced that it has secured a $25 million Series D financing to support the commencement of its Phase 3 ADAPT study in patients with newly diagnosed, metastatic renal cell carcinoma (mRCC) in mid-2012. The financing was led by Forbion Capital and included other existing investors, including TVM Capital, Lumira Capital, Intersouth Partners, Caisse de depot et placement du Quebec, Morningside Group, and Aurora Funds....

2012-03-29 22:10:17

Patients with papillary renal cell carcinoma, the second most common kidney cancer subtype, face a low risk of tumor recurrence and cancer-related death after surgery. Those are the key findings of a multi-centre study of nearly 600 patients published in the April issue of the urology journal BJUI. "Because papillary renal cell carcinoma (pRCC) only affects ten to 15% of kidney cancer patients, the small number of patients enrolled in individual studies makes it hard to draw meaningful...